metastatic castration-resistant prostate cancer Prostate cancer prostate cancer
Conditions
Interventions
This study aims to collect data about the use of Lu-PSMA. The treatments that patients receive are part of regular clinical care and not affected by participation in the study.
Sponsors
Erasmus MC, Universitair Medisch Centrum Rotterdam
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: - Participants should be at least 18 years old. - Participants should be able to understand the written information and be able to provide informed consent. - Participants are planned to start treatment with Lu-PSMA as a part of regular clinical care.
Exclusion criteria
Exclusion criteria: None Applicable
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The present study is observational in nature. The study tracks overall survival as endpoint to assess the efficacy of treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression free survival on the basis of clinical data, radiological imaging as well as PSA. Heterogeneity of PSMA-positivity in circulating tumor cells (CTC) prior to treatment with Lutetium-PSMA. Association between ctDNA in blood and other biomarkers with treatment outcomes of Lutetium-PSMA treatment. Association between PSMA-PET and therapy scans with treatment outcomes of Lutetium-PSMA treatment. Validation of the use of dried blood spots to measure blood concentration of Lu-177 during use of Lu-PSMA. | — |
Countries
Netherlands
Contacts
Public ContactK.R. Doornhof
Erasmus MC, Universitair Medisch Centrum Rotterdam
Outcome results
None listed